What Makes Alignment Healthcare (ALHC) a Strong Momentum Stock: Buy Now?
Does Alignment Healthcare (ALHC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Alignment Healthcare, Inc. (ALHC) Q2 2025 Earnings Call Transcript
Alignment Healthcare, Inc. (NASDAQ:ALHC ) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants John E. Kao - Founder, CEO & Director James M.
Alignment Healthcare (ALHC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Alignment Healthcare (ALHC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alignment Healthcare (ALHC) Q2 Earnings and Revenues Surpass Estimates
Alignment Healthcare (ALHC) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to a loss of $0.13 per share a year ago.
Alignment Healthcare: Secular Growth Opportunity And Scalable Business Model
Alignment Healthcare is well-positioned for growth, benefiting from an aging U.S. population and increasing demand for high-quality senior healthcare services. Strong membership growth and high CMS star ratings support its expansion into new regions. Stock price has upside opportunity based on the company's revenue and membership growth guidance.
Most Managed Care Insurers Expected To See Q2 2025 Drops In Revenue, Net Income
A majority of publicly traded US health insurers are expected to post QoQ declines in revenue and net income in Q2, according to an S&P Global Market Intelligence analysis of sell-side analyst forecasts. Of the eight largest publicly traded US managed care insurers, all but two — UnitedHealth Group and Alignment Healthcare — are projected to report lower revenue compared with Q1 2025, while all eight are forecast to log higher revenue than Q2 2024. In Q2, all eight of the largest publicly traded US managed care insurers, except The Cigna Group, are expected to log lower net income sequentially, while all eight are forecast to report lower net income YoY.
Alignment Healthcare (ALHC) Upgraded to Buy: Here's What You Should Know
Alignment Healthcare (ALHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
Here is how Alignment Healthcare (ALHC) and BridgeBio Pharma (BBIO) have performed compared to their sector so far this year.
Compared to Estimates, Alignment Healthcare (ALHC) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alignment Healthcare (ALHC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates
Alignment Healthcare (ALHC) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.25 per share a year ago.
All You Need to Know About Alignment Healthcare (ALHC) Rating Upgrade to Buy
Alignment Healthcare (ALHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alignment Healthcare (ALHC) Surges 6.3%: Is This an Indication of Further Gains?
Alignment Healthcare (ALHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
